| [1] |
Cochrane DR, Bernales S, Jacobsen BM, et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide[J].Breast Cancer Res,2014,16(1):R7.
|
| [2] |
Aleskandarany MA, Abduljabbar R, Ashankyty I, et al. Prognostic significance of androgen receptor expression in invasive breast cancer:transcriptomic and protein expression analysis[J]. Breast Cancer Res Treat,2016,159(2):215-227.
|
| [3] |
Gucalp A, Tolaney S, Isakoff SJ, et al. Phase Ⅱtrial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer [J]. Clin Cancer Res, 2013,19 (19):5505-5512.
|
| [4] |
Pietri E, Conteduca V, Andreis D, et al. Androgen receptor signaling pathways as a target for breast cancer treatment[J]. Endocr Relat Cancer,2016,23(10):R485-498.
|
| [5] |
Collins LC, Cole KS, Marotti JD, et al. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study[J]. Mod Pathol,2011,24(7):924-931.
|
| [6] |
Tsang JY,Ni YB,Chan SK,et al. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers[J].Ann Surg Oncol,2014,21(7):2218-2228.
|
| [7] |
Castellano I, Chiusa L, Vandone AM, et al. A simple and reproducible prognostic index in luminal ER-positive breast cancers[J]. Ann Oncol,2013,24(9):2292-2297.
|
| [8] |
Lim E, Ni M,Cao S, et al. Importance of breast cancer subtype in the development of androgen receptor directed therapy[J]. Curr Breast Cancer Rep,2014,6(2):71-78.
|
| [9] |
Risbridger GP, Davis ID, Birrell SN, et al. Breast and prostate cancer: more similar than different [J]. Nat Rev Cancer, 2010,10(3):205-212.
|
| [10] |
Peters AA, Buchanan G, Ricciardelli C, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer[J]. Cancer Res,2009,69(15):6131-6140.
|
| [11] |
Need EF, Selth LA, Harris TJ, et al. Research resource: interplay between the genomic and transcriptional networks of androgen receptor and estrogen receptor alpha in luminal breast cancer cells[J]. Mol Endocrinol,2012,26(11):1941-1952.
|
| [12] |
D'Amato NC, Gordon MA, Babbs B, et al. Cooperative dynamics of AR and ER activity in breast cancer[J]. Mol Cancer Res,2016,14(11):1054-1067.
|
| [13] |
Rizza P, Barone I, Zito D, et al. Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines[J]. Breast Cancer Res,2014,16(1):R21.
|
| [14] |
Chia K, O'Brien M, Brown M, et al. Targeting the androgen receptor in breast cancer[J]. Curr Oncol Rep,2015,17(2):4.
|
| [15] |
Lanzino M, Sisci D, Morelli C, et al. Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element[J]. Nucleic Acids Res, 2010,38(16):5351-5365.
|
| [16] |
Garay JP, Park BH. Androgen receptor as a targeted therapy for breast cancer[J]. Am J Cancer Res,2012,2(4):434-445.
|
| [17] |
Glaser RL,Dimitrakakis C. Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole:a prospective, observational study[J]. Maturitas, 2013,76 (4):342-349.
|
| [18] |
Overmoyer B, Sanzaltimira P,Partridge AH,et al. Abstract P1-13-04:enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. final results of the primary endpoint and current progression free survival [J]. Cancer Res, 2015,75(9 Suppl):P1-13.
|
| [19] |
Garay JP, Karakas B, Abukhdeir AM, et al. The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation[J]. Breast Cancer Res,2012,14(1):R27.
|
| [20] |
Moerkens M, Zhang Y, Wester L, et al. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor alpha signalling and results in tamoxifen insensitive proliferation[J]. BMC Cancer,2014,14:283.
|
| [21] |
Ciupek A, Rechoum Y, Gu G, et al. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer[J]. Breast Cancer Res Treat,2015,154(2):225-237.
|
| [22] |
O'Shaughnessy J, Campone M, Brain E, et al. Abiraterone acetate,exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer [J]. Ann Oncol, 2016,27(1):106-113.
|
| [23] |
Yu Q, Niu Y, Liu N, et al. Expression of androgen receptor in breast cancer and its significance as a prognostic factor[J]. Ann Oncol,2011,22(6):1288-1294.
|
| [24] |
Vera-Badillo FE, Templeton AJ, de Gouveia P, et al. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis[J]. J Natl Cancer Inst, 2014,106(1):djt319.
|
| [25] |
Ni M, Chen Y, Lim E, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer[J]. Cancer Cell,2011,20(1):119-131.
|
| [26] |
Ni M, Chen Y, Fei T, et al. Amplitude modulation of androgen signaling by c-MYC[J]. Genes Dev,2013,27(7):734-748.
|
| [27] |
Anestis A,Karamouzis MV,Dalagiorgou G,et al. Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer? [J]. Cancer Treat Rev,2015,41(6):547-553.
|
| [28] |
Zhu A, Li Y, Song W, et al. Antiproliferative effect of androgen receptor inhibition in mesenchymal stem-like triple-negative breast cancer[J]. Cell Physiol Biochem,2016,38(3):1003-1014.
|
| [29] |
Choi JE, Kang SH, Lee SJ, et al. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer[J]. Ann Surg Oncol,2015,22(1):82-89.
|
| [30] |
Gasparini P, Fassan M, Cascione L, et al. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options[J]. PLoS One, 2014,9(2):e88525.
|
| [31] |
Zhang L, Fang C, Xu X, et al. Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis[J]. Biomed Res Int,2015,2015:357 485.
|
| [32] |
Lehmann BD,Bauer JA, Chen X,et al. Identification of human triplenegative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest,2011,121(7):2750-2767.
|
| [33] |
Lehmann-Che J, Hamy AS, Porcher R, et al. Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15[J]. Breast Cancer Res,2013,15(3):R37.
|
| [34] |
Fioretti FM, Sita-Lumsden A, Bevan CL, et al. Revising the role of the androgen receptor in breast cancer[J]. J Mol Endocrinol, 2014,52(3):R257-265.
|
| [35] |
Robinson JL, Macarthur S, Ross-Innes CS, et al. Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1[J]. EMBO J,2011,30(15):3019-3027.
|
| [36] |
Traina TA, O'Shaughnessy J, Nanda R, et al. Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor(AR) inhibitor, in advanced AR + triple-negative breast cancer(TNBC)[J]. Cancer Res,2015,75(9 suppl):P5-19-09.
|